Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Studying Different Formulations of SR13668 in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00896207
First received: May 8, 2009
Last updated: October 7, 2014
Last verified: October 2011

May 8, 2009
October 7, 2014
June 2009
March 2010   (final data collection date for primary outcome measure)
  • Food effect on the bioavailability of SR13668 after oral administration [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
    The first stage will be used to compare fed vs. fasted diet effect on the pharmacokinetics parameters under formulation 1.
  • Formulation effect on the bioavailability of SR13668 after oral administration [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
    The second stage will be used to determine the formulation effects on the pharmacokinetics parameters, all under either fed or fasted diet as determined by the first stage.
Determination of which oral formulation of Akt inhibitor SR13668 provides the best bioavailability in normal, healthy volunteers [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00896207 on ClinicalTrials.gov Archive Site
  • Solubility and stability of Akt inhibitor SR13668 in oral formulations selected for exploratory pharmacokinetics studies [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
  • Oral pharmacokinetics of a single low dose of Akt inhibitor SR13668 [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
  • Metabolism of Akt inhibitor SR13668 [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
  • Preliminary safety data for Akt inhibitor SR13668, graded according to NCI CTCAE version 3.0 [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: Yes ]
  • Solubility and stability of Akt inhibitor SR13668 in oral formulations selected for exploratory pharmacokinetics studies [ Designated as safety issue: No ]
  • Oral pharmacokinetics of a single low dose of Akt inhibitor SR13668 [ Designated as safety issue: No ]
  • Metabolism of Akt inhibitor SR13668 [ Designated as safety issue: No ]
  • Preliminary safety data for Akt inhibitor SR13668 [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Studying Different Formulations of SR13668 in Healthy Volunteers
Single-Dose Phase 0 Exploratory Pharmacokinetic Clinical Trial Comparing Five Oral Formulations of SR13668, an Orally Active AKT Pathway Inhibitor

This randomized early phase I trial is studying different formulations of SR13668 in healthy volunteers. Giving SR13668 may help doctors learn more about how SR13668 is used by the body. It is not yet known which formulation of SR13668 is most effectively used by the body.

PRIMARY OBJECTIVES:

I. Determine which oral formulation of Akt inhibitor SR13668 provides the best bioavailability in normal, healthy volunteers.

SECONDARY OBJECTIVES:

I. Determine the oral pharmacokinetics of a single, low dose of Akt inhibitor SR13668 in healthy volunteers.

II. Characterize the metabolism of Akt inhibitor SR13668 in healthy volunteers. III. Collect preliminary safety data for Akt inhibitor SR13668 in healthy volunteers.

OUTLINE:

STAGE 1 (for the first 6 participants enrolled in the study [closed to accrual as of August, 2009]): Participants are randomized to 1 of 2 arms.

ARM I: Participants complete an overnight fast of ≥ 10 hours, eat a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800-1,000 calories), and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.

ARM II: Participants complete an overnight fast of ≥ 10 hours and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.

STAGE 2 (for the next 12 participants enrolled in the study): The preferred dietary condition (Arm I) identified in stage 1 is used. Participants are randomized to 1 of 4 arms.

ARM III: Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol® self-emulsifying solid dispersion capsule formulation.

ARM IV: Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol®/vitamin E TGPS self-emulsifying solid dispersion capsule formulation.

ARM V: Participants receive a single dose of oral Akt inhibitor SR13668 in a vitamin E TGPS self-emulsifying solid dispersion capsule formulation.

ARM VI: Participants receive a single dose of oral Akt inhibitor SR13668 in a Myrj 53 self-emulsifying solid dispersion capsule formulation.

Blood and urine samples are collected at baseline and periodically during the 24 hours after study drug administration for pharmacokinetic analysis by high performance liquid chromatography assay.

After completion of study treatment, participants are followed by telephone at 7-10 days and at 30 days.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy, no Evidence of Disease
Drug: Akt inhibitor SR13668
Given orally as a single dose
Other Name: SRI13668
  • Experimental: Arm I
    Participants complete an overnight fast of ≥ 10 hours, eat a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800-1,000 calories) meal, and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
    Intervention: Drug: Akt inhibitor SR13668
  • Experimental: Arm II
    Participants complete an overnight fast of ≥ 10 hours and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
    Intervention: Drug: Akt inhibitor SR13668
  • Experimental: Arm III
    Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol® self-emulsifying solid dispersion capsule formulation.
    Intervention: Drug: Akt inhibitor SR13668
  • Experimental: Arm IV
    Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol®/vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
    Intervention: Drug: Akt inhibitor SR13668
  • Experimental: Arm V
    Participants receive a single dose of oral Akt inhibitor SR13668 in a vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
    Intervention: Drug: Akt inhibitor SR13668
  • Experimental: Arm VI
    Participants receive a single dose of oral Akt inhibitor SR13668 in a Myrj 53 self-emulsifying solid dispersion capsule formulation.
    Intervention: Drug: Akt inhibitor SR13668
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
March 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteer
  • ECOG performance status 0
  • Leukocyte count ≥ 3,000/mm^3
  • ANC ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin normal
  • Alkaline phosphatase ≤ 1.5 times upper limit of normal (ULN)
  • ALT ≤ 1.5 times ULN
  • Direct bilirubin ≤ 1.5 times ULN
  • Sodium ≤ 1.5 times ULN
  • Potassium ≤ 1.5 times ULN
  • Creatinine ≤ 1.5 times ULN OR calculated creatinine clearance ≥ 30 mL/min
  • Fasting blood glucose normal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile participants must use effective barrier contraception
  • Able and willing to fast overnight prior to study drug administration AND consume a high-fat meal on the day of study drug administration
  • Willing to provide required blood and urine samples AND stay all day and overnight in the Clinical Research Unit
  • Willing to abstain from alcoholic beverages and caffeine for ≥ 24 hours prior to study drug administration and until all blood and urine samples have been collected
  • No cancer within the past 3 years except for nonmelanoma skin cancer, localized prostate cancer, superficial bladder cancer, or carcinoma in situ of the cervix
  • No concurrent uncontrolled illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Severe chronic obstructive pulmonary disease requiring supplemental oxygen
    • Hypertension that is difficult to control
    • Psychiatric illness or social situation that would limit compliance with study requirements
  • No diabetes mellitus
  • No other condition that may, in the investigator's opinion, interfere with ingestion or absorption of oral medications (e.g., inflammatory bowel disease)
  • No history of allergic-type reactions, including asthma and urticaria, or other intolerance to chemical compounds similar to the active study agent, indole-3-carbinol, or cruciferous vegetables (e.g., cabbage, cauliflower, broccoli, kale, and Brussels sprouts)
  • More than 6 months since prior investigational agents
  • More than 3 months since prior oral contraceptives (including Plan B method of contraception)

    • No concurrent hormonal contraception
  • More than 14 days since prior and no concurrent anticoagulant or antiplatelet medications
  • More than 7 days since prior and no concurrent daily medications or nutritional supplements
  • No prior gastrectomy that may, in the investigator's opinion, interfere with ingestion or absorption of oral medications
  • No other concurrent medications
Both
18 Years to 62 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00896207
NCI-2009-01106, NCI-2009-01106, MAYO-MAY07-9-01, CDR0000638390, MAY-07-9-01, MAYO-MAY07-9-01, MAY07-9-01, P30CA015083
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Paul Limburg Mayo Clinic
National Cancer Institute (NCI)
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP